Browsing Tag
REVLIMID
8 posts
Bristol Myers Squibb myeloma drug doubles progression-free survival in pivotal SUCCESSOR-2 trial
Bristol Myers Squibb's mezigdomide doubled myeloma progression-free survival to 18 months and cut progression or death risk 52% in Phase 3, key to its patent-cliff plan.
Natco Pharma completes full US generic Revlimid lineup with new lenalidomide strengths
Natco Pharma and Teva Pharmaceuticals launch 2.5 mg and 20 mg generic lenalidomide in US, completing their Revlimid portfolio for multiple myeloma treatment.
Dr Reddy’s Labs announces limited volume US launch of Lenalidomide Capsules
Dr Reddy’s Laboratories said that it has launched two of six strengths of cancer medication Lenalidomide Capsules, a…
Natco Pharma launches PrNAT-LENALIDOMIDE Capsules in Canada
Natco Pharma Limited has announced the Canadian launch of PrNAT-LENALIDOMIDE Capsules, a generic version of Celgene Corporation’s cancer…
Zydus Cadila gets FDA approval for Revlimid generic Lenalidomide Capsules
Zydus Cadila said that the US Food and Drug Administration (FDA) has granted it tentative approval for Lenalidomide…
Sun Pharma to settle patent litigation with Celgene for generic Revlimid
Sun Pharmaceutical Industries (Sun Pharma) along with one of its fully-owned subsidiaries has reached an agreement with Celgene,…
Natco Pharma gets FDA approval for Lenalidomide Capsules
Natco Pharma has secured the final approval from the US Food and Drug Administration (FDA) of its abbreviated…
Bristol-Myers Squibb to acquire Celgene in $74bn pharma megadeal
Bristol-Myers Squibb has reached a definitive agreement to acquire Celgene Corporation in a monumental cash-and-stock deal worth approximately…